News Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			Pre-market 07:25:24 am
193.2 ^USD	-0.48%		202.4	+4.76%

12:45pm	Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	RE
12:06pm	S&P, Nasdaq futures advance on tech boost, earnings cheer	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	06:45am	RE
S&P, Nasdaq futures advance on tech boost, earnings cheer	06:06am	RE
Alzheimer's drug adoption in US slowed by doctors' skepticism	Apr. 23	RE
Needham Adjusts Price Target on Biogen to $294 From $300	Apr. 19	MT
BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept	Apr. 19	MT
Oppenheimer Adjusts Biogen Price Target to $270 From $290	Apr. 19	MT
UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating	Apr. 17	MT
Wedbush Cuts Biogen's Price Target to $213 From $245	Apr. 17	MT
Argus Adjusts Biogen's Price Target to $240 From $315	Apr. 15	MT
Goldman Sachs Cuts Biogen's Price Target to $393 From $400	Apr. 15	MT
JPMorgan Cuts Biogen's Price Target to $240 From $270, Maintains Neutral Rating	Apr. 11	MT
Morgan Stanley Trims Price Target on Biogen to $339 From $346, Keeps Overweight Rating	Apr. 09	MT
Barclays Cuts Price Target on Biogen to $215 From $230, Maintains Equalweight Rating	Apr. 04	MT
Sector Update: Health Care Stocks Higher Prebell Monday	Apr. 01	MT
Sector Update: Health Care	Apr. 01	MT
Biogen Partner Eisai Submits Supplemental Biologics License Application for Leqembi to FDA	Apr. 01	MT
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	Mar. 31	PR
Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell	Mar. 25	MT
Biogen : Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application	Mar. 22	PU
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 21	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biogen Inc.

Equities

BIIB

US09062X1037

Summary

Filters